Dr. Saab on Napabucasin (BBI-608) in Colorectal Cancer Treatment

Tanios Bekaii-Saab, MD
Published: Tuesday, Jun 20, 2017



Tanios Bekaii-Saab, MD, professor of Medicine, Mayo Clinic, discusses the stemness inhibitor napabucasin (BBI-608) as a potential treatment for patients with colorectal cancer (CRC).

A phase III study that investigated single-agent napabucasin versus placebo did not reach its primary endpoint, Bekaii-Saab explains. However, in the patients with the p-STAT3 expression, it was found that the hazard ratio was .21, telling researchers that the mechanism of action of this drug perhaps is what's leading the clinical activity in this patient population. When this agent is combined with chemotherapy, the STAT3 expression is not as significant, he adds.

Therefore, there are other synergy levels with chemotherapy and other biomarkers that are being explored.


Tanios Bekaii-Saab, MD, professor of Medicine, Mayo Clinic, discusses the stemness inhibitor napabucasin (BBI-608) as a potential treatment for patients with colorectal cancer (CRC).

A phase III study that investigated single-agent napabucasin versus placebo did not reach its primary endpoint, Bekaii-Saab explains. However, in the patients with the p-STAT3 expression, it was found that the hazard ratio was .21, telling researchers that the mechanism of action of this drug perhaps is what's leading the clinical activity in this patient population. When this agent is combined with chemotherapy, the STAT3 expression is not as significant, he adds.

Therefore, there are other synergy levels with chemotherapy and other biomarkers that are being explored.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: The Next Generation in Renal Cell Carcinoma Treatment: An Oncology Nursing Essentials WorkshopJul 31, 20181.5
Publication Bottom Border
Border Publication
x